Unveiling 11 Analyst Insights On Bristol-Myers Squibb
Portfolio Pulse from Benzinga Insights
Analysts have mixed views on Bristol-Myers Squibb (NYSE:BMY) with recent evaluations showing a range of sentiments. The average 12-month price target has increased slightly to $48.0. The company's financial health shows strong net margins and ROA, but challenges in ROE and revenue growth compared to peers.
October 07, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bristol-Myers Squibb has received mixed analyst ratings with a slight increase in the average price target to $48.0. The company shows strong net margins and ROA but faces challenges in ROE and revenue growth compared to peers.
The mixed analyst ratings indicate uncertainty in the market's perception of BMY. The slight increase in the average price target suggests a modest positive outlook. However, the company's challenges in ROE and revenue growth compared to peers may offset the positive sentiment from strong net margins and ROA.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100